The multi-antigen panels and gating strategies currently employed at MD Anderson for the detection of BPDCN were recently described in detail and include the markers CD4, CD33, CD45, CD56, CD64, CD123, CD303, and HLA-DR. This evidence concerns the gene CLEC4C and CD4+/CD56+ hematodermic neoplasm.